President Trump signed the sweeping opioid legislation into law Wednesday afternoon at a White House ceremony. It was a very well attended event, including Cabinet members, legislators, leadership from our field and business leaders, especially from the large pharmacy retail groups.
Mrs. Trump also made opening remarks reflecting the work of the people behind the podium, including our own Dr. Loretta Finnegan, for her work in the MATER program in Philadelphia, treating women and their children.
It represented a lovely acknowledgement of Dr. Finnegan’s work in our field in developing the earliest comprehensive treatment program, specializing in the treatment of women suffering from opioid use disorder.
President Trump provided a summary of the major components of the bill and also cited the work of his administration. From our point of view, one of the major elements of the package authorizes the development of a Medicare reimbursement rate for OTP services and medications when treating Medicare eligible patients in OTPs.
Thank you once again for your support and your letters to so many elected officials. Our patients are the ultimate beneficiaries.